| scholarly article | Q13442814 |
| P2093 | author name string | Geraint T Williams | |
| John D Williams | |||
| Nicholas Topley | |||
| Kathrine J Craig | |||
| Ruth K Mackenzie | |||
| Geoffrey R Newman | |||
| Christopher Von Ruhland | |||
| Maureen Fallon | |||
| Peritoneal Biopsy Study Group | |||
| P433 | issue | 2 | |
| P921 | main subject | kidney disease | Q1054718 |
| P304 | page(s) | 470-479 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Morphologic changes in the peritoneal membrane of patients with renal disease | |
| P478 | volume | 13 |
| Q42679595 | 1,25(OH)2D3 treatment attenuates high glucose‑induced peritoneal epithelial to mesenchymal transition in mice |
| Q41105771 | 22-Oxacalcitriol prevents progression of peritoneal fibrosis in a mouse model |
| Q36260973 | A Novel Mouse Model of Peritoneal Dialysis: Combination of Uraemia and Long-Term Exposure to PD Fluid |
| Q34787745 | A pathogenetic role for endothelin-1 in peritoneal dialysis-associated fibrosis |
| Q42025925 | A peritoneal dialysis regimen low in glucose and glucose degradation products results in increased cancer antigen 125 and peritoneal activation |
| Q52908558 | Abatacept as a therapeutic option in the treatment of encapsulated peritoneal sclerosis: an experimental rat model. |
| Q54441131 | Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients. |
| Q91813275 | Activation of General Control Nonderepressible-2 Kinase Ameliorates Glucotoxicity in Human Peritoneal Mesothelial Cells, Preserves Their Integrity, and Prevents Mesothelial to Mesenchymal Transition |
| Q37151547 | Activation of salt-inducible kinase 2 promotes the viability of peritoneal mesothelial cells exposed to stress of peritoneal dialysis |
| Q51287793 | Active compounds extracted from extra virgin olive oil counteract mesothelial-to-mesenchymal transition of peritoneal mesothelium cells exposed to conventional peritoneal dialysate: in vitro and in vivo evidences. |
| Q36380165 | Alteration of membrane complement regulators is associated with transporter status in patients on peritoneal dialysis |
| Q35647422 | Alterations of intercellular junctions in peritoneal mesothelial cells from patients undergoing dialysis: effect of retinoic Acid |
| Q64994081 | Analysis of the Ribonuclease A Superfamily of Antimicrobial Peptides in Patients Undergoing Chronic Peritoneal Dialysis. |
| Q42046471 | Are the Mesothelial-to-Mesenchymal Transition, Sclerotic Peritonitis Syndromes, and Encapsulating Peritoneal Sclerosis Part of the Same Process? |
| Q48114520 | Autophagy promotes fibrosis and apoptosis in the peritoneum during long-term peritoneal dialysis. |
| Q24795280 | BIOKID: randomized controlled trial comparing bicarbonate and lactate buffer in biocompatible peritoneal dialysis solutions in children [ISRCTN81137991] |
| Q35106066 | Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients. |
| Q42722791 | Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis |
| Q47159158 | Bicarbonate buffered peritoneal dialysis fluid upregulates angiopoietin-1 and promotes vessel maturation |
| Q53313808 | Biocompatible Dialysis Solutions Preserve Peritoneal Mesothelial Cell and Vessel Wall Integrity. A Case-Control Study on Human Biopsies. |
| Q61450664 | Biocompatible Peritoneal Dialysis: The Target Is Still Way Off |
| Q57293923 | Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport |
| Q38068420 | Biocompatible peritoneal dialysis fluids: clinical outcomes. |
| Q35210203 | Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage |
| Q53182076 | Buffer-dependent regulation of aquaporin-1 expression and function in human peritoneal mesothelial cells. |
| Q37232288 | Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients? |
| Q35805756 | Can peritoneal dialysis be used as a long term therapy for end stage renal disease? |
| Q44869313 | Can sonographic peritoneal thickness be used to follow pediatric patients on peritoneal dialysis? |
| Q37288876 | Changes in expression of four molecular marker proteins and one microRNA in mesothelial cells of the peritoneal dialysate effluent fluid of peritoneal dialysis patients |
| Q40790185 | Chondroitin sulfate prevents peritoneal fibrosis in mice by suppressing NF-κB activation |
| Q81607635 | Chronic abdominal pain in a patient on chronic peritoneal dialysis: answer |
| Q37000841 | Chronic infusion of sterile peritoneal dialysis solution abrogates enhanced peritoneal gene expression responses to chronic peritoneal catheter presence |
| Q38217488 | Clinical causes of inflammation in peritoneal dialysis patients |
| Q37148900 | Concomitant bidirectional transport during peritoneal dialysis can be explained by a structured interstitium. |
| Q92757529 | Connective tissue growth factor is correlated with peritoneal lymphangiogenesis |
| Q36162706 | Cross-omics comparison of stress responses in mesothelial cells exposed to heat- versus filter-sterilized peritoneal dialysis fluids |
| Q91968506 | Crucial Role of NLRP3 Inflammasome in the Development of Peritoneal Dialysis-related Peritoneal Fibrosis |
| Q37123283 | Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane |
| Q52653624 | Deficiency of endothelial nitric oxide signaling pathway exacerbates peritoneal fibrosis in mice. |
| Q36686001 | Diabetes influences peritoneal morphology in uremic patients at the initiation of peritoneal dialysis |
| Q51158179 | Dialysate CA125 levels after 5 years on continuous peritoneal dialysis. |
| Q44118964 | Dialysate CA125 levels in children on continuous peritoneal dialysis |
| Q34182897 | Dialysate cytokine levels do not predict encapsulating peritoneal sclerosis |
| Q37485572 | Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients |
| Q55179492 | Differences in peritoneal response after exposure to low-GDP bicarbonate/lactate-buffered dialysis solution compared to conventional dialysis solution in a uremic mouse model. |
| Q89397321 | Differences in peritoneal solute transport rates in peritoneal dialysis |
| Q36061883 | Effect of aldosterone on epithelial-to-mesenchymal transition of human peritoneal mesothelial cells |
| Q35798426 | Effect of bevacizumab, a vascular endothelial growth factor inhibitor, on a rat model of peritoneal sclerosis |
| Q83974853 | Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model |
| Q90470242 | Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients |
| Q38487275 | Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD? |
| Q38228157 | Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review. |
| Q48223537 | Effluent and serum protein N-glycosylation is associated with inflammation and peritoneal membrane transport characteristics in peritoneal dialysis patients |
| Q34725172 | Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study |
| Q34816520 | Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease. |
| Q95361164 | Encapsulating peritoneal sclerosis: the state of affairs |
| Q52929684 | Endoplasmic reticulum stress as a novel target to ameliorate epithelial-to-mesenchymal transition and apoptosis of human peritoneal mesothelial cells. |
| Q93088703 | Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis |
| Q28066669 | Experimental systems to study the origin of the myofibroblast in peritoneal fibrosis |
| Q34427394 | Fibrin-Induced epithelial-to-mesenchymal transition of peritoneal mesothelial cells as a mechanism of peritoneal fibrosis: effects of pentoxifylline |
| Q54343799 | Fluvastatin inhibits the expression of fibronectin in human peritoneal mesothelial cells induced by high-glucose peritoneal dialysis solution via SGK1 pathway. |
| Q42116828 | Functional effector memory T cells enrich the peritoneal cavity of patients treated with peritoneal dialysis |
| Q34667822 | Functional relevance of the switch of VEGF receptors/co-receptors during peritoneal dialysis-induced mesothelial to mesenchymal transition |
| Q46394494 | Gremlin promotes peritoneal membrane injury in an experimental mouse model and is associated with increased solute transport in peritoneal dialysis patients |
| Q45003963 | Heme oxygenase-1 attenuates epithelial-to-mesenchymal transition of human peritoneal mesothelial cells |
| Q35528907 | Hepatocyte growth factor signalizes peritoneal membrane failure in peritoneal dialysis. |
| Q33634860 | High-dialysate-glucose-induced oxidative stress and mitochondrial-mediated apoptosis in human peritoneal mesothelial cells |
| Q39117321 | Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction |
| Q34110645 | Histological and clinical findings in patients with post-transplantation and classical encapsulating peritoneal sclerosis: a European multicenter study. |
| Q36885500 | Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis |
| Q46525336 | Histone deacetylase 6 inhibition counteracts the epithelial-mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis |
| Q33790023 | Human Peritoneal Mesothelial Cell Death Induced by High-Glucose Hypertonic Solution Involves Ca2+ and Na+ Ions and Oxidative Stress with the Participation of PKC/NOX2 and PI3K/Akt Pathways |
| Q39373839 | Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors |
| Q55492130 | Human umbilical cord mesenchymal stem cells facilitate the up-regulation of miR-153-3p, whereby attenuating MGO-induced peritoneal fibrosis in rats. |
| Q97529188 | Hypochlorite-induced porcine model of peritoneal fibrosis through the activation of IL1β-CX3CL1-TGFβ1 signal axis |
| Q37261611 | IL-10 differentially controls the infiltration of inflammatory macrophages and antigen-presenting cells during inflammation |
| Q59808760 | IL-17 in Peritoneal Dialysis-Associated Inflammation and Angiogenesis: Conclusions and Perspectives |
| Q40455037 | IL-6 Trans-Signaling Links Inflammation with Angiogenesis in the Peritoneal Membrane. |
| Q52871286 | Identification of Gene Transcripts Implicated in Peritoneal Membrane Alterations. |
| Q39789853 | Immune-Regulatory Molecule CD69 Controls Peritoneal Fibrosis. |
| Q57998099 | Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis |
| Q35524698 | Impact of a low-glucose peritoneal dialysis regimen on fibrosis and inflammation biomarkers. |
| Q38528380 | Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology |
| Q36474338 | Increased lymphatic vessels in patients with encapsulating peritoneal sclerosis |
| Q52905130 | Increased storage and secretion of phosphatidylcholines by senescent human peritoneal mesothelial cells. |
| Q28082263 | Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions |
| Q36475710 | Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells |
| Q59420998 | Influence of local inflammation of the peritoneal membrane on diuresis and residual renal function in patients treated with peritoneal dialysis |
| Q33906324 | Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis |
| Q40974170 | Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis |
| Q36302660 | Inhibition of H3K9 methyltransferase G9a ameliorates methylglyoxal-induced peritoneal fibrosis |
| Q54972703 | Inhibition of the H3K4 methyltransferase SET7/9 ameliorates peritoneal fibrosis. |
| Q38474258 | Interference of peritoneal dialysis fluids with cell cycle mechanisms |
| Q37572817 | Interleukin-6 signaling drives fibrosis in unresolved inflammation |
| Q36104878 | Interstitial Fibrosis Restricts Osmotic Water Transport in Encapsulating Peritoneal Sclerosis |
| Q40950611 | Involvement of leptin in the progression of experimentally induced peritoneal fibrosis in mice |
| Q38976940 | Is there such a thing as biocompatible peritoneal dialysis fluid? |
| Q41066392 | Level of 8-OHdG in drained dialysate appears to be a marker of peritoneal damage in peritoneal dialysis |
| Q36101582 | Linagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in Mice |
| Q34568791 | Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury |
| Q91970999 | Longitudinal Changes of NF-κB Downstream Mediators and Peritoneal Transport Characteristics in Incident Peritoneal Dialysis Patients |
| Q37669430 | Longitudinal analysis of peritoneal fluid transport and its determinants in a cohort of incident peritoneal dialysis patients |
| Q37553046 | Longitudinal study of small solute transport and peritoneal protein clearance in peritoneal dialysis patients |
| Q42777149 | Low-protein diet supplemented with keto acids is associated with suppression of small-solute peritoneal transport rate in peritoneal dialysis patients |
| Q39757996 | Matrix metalloproteinase 9 is associated with peritoneal membrane solute transport and induces angiogenesis through β-catenin signaling |
| Q37936293 | Mechanisms and interventions in peritoneal fibrosis |
| Q88910016 | Mechanisms of Crystalloid versus Colloid Osmosis across the Peritoneal Membrane |
| Q37046408 | Mechanisms of epithelial-mesenchymal transition of peritoneal mesothelial cells during peritoneal dialysis. |
| Q28390104 | Mesenchymal Conversion of Mesothelial Cells Is a Key Event in the Pathophysiology of the Peritoneum during Peritoneal Dialysis |
| Q37064631 | Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signaling |
| Q28566510 | Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6 |
| Q28088764 | Mesothelial cells in tissue repair and fibrosis |
| Q33915937 | Metformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress. |
| Q64076321 | MiR-200a ameliorates peritoneal fibrosis and functional deterioration in a rat model of peritoneal dialysis |
| Q38306582 | MiR-30b is involved in methylglyoxal-induced epithelial-mesenchymal transition of peritoneal mesothelial cells in rats. |
| Q53797400 | MicroRNA-29b inhibits peritoneal fibrosis in a mouse model of peritoneal dialysis. |
| Q64279378 | MicroRNA-302c modulates peritoneal dialysis-associated fibrosis by targeting connective tissue growth factor |
| Q48228157 | Morphologic characteristics of macroscopic peritoneal finding in patients with peritoneal dialysis. |
| Q53609087 | Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution. |
| Q36395966 | Multiple extracellular vesicle types in peritoneal dialysis effluent are prominent and contain known biomarkers. |
| Q35955204 | NFAT5 contributes to osmolality-induced MCP-1 expression in mesothelial cells |
| Q36475570 | Neuropeptide release augments serum albumin loss and reduces ultrafiltration in peritoneal dialysis |
| Q36831478 | Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis |
| Q42492768 | New Insights into the Effects of Chronic Kidney Failure and Dialysate Exposure on the Peritoneum |
| Q26780145 | New developments in peritoneal fibroblast biology: implications for inflammation and fibrosis in peritoneal dialysis |
| Q42002311 | New insights into therapeutic strategies for the treatment of peritoneal fibrosis: learning from histochemical analyses of animal models |
| Q43097848 | Normal peritoneal histology after ten years of peritoneal dialysis in a contemporary Japanese patient |
| Q42797305 | Normal peritoneum after nine years of peritoneal dialysis with biocompatible dialysate: a case report |
| Q57293924 | PD Solutions and Peritoneal Health |
| Q40332594 | Pathological changes in chronic eosinophilic peritonitis in peritoneal dialysis patient |
| Q35915748 | Pathophysiological changes to the peritoneal membrane during PD-related peritonitis: the role of mesothelial cells. |
| Q21296812 | Pathophysiology of the peritoneal membrane during peritoneal dialysis: the role of hyaluronan |
| Q34482573 | Patients with encapsulating peritoneal sclerosis have increased peritoneal expression of connective tissue growth factor (CCN2), transforming growth factor-β1, and vascular endothelial growth factor. |
| Q33701827 | Periostin-Binding DNA Aptamer Treatment Ameliorates Peritoneal Dialysis-Induced Peritoneal Fibrosis |
| Q51682614 | Peritoneal Dialysis Catheter Increases Leukocyte Recruitment in the Mouse Parietal Peritoneum Microcirculation and Causes Fibrosis. |
| Q42430642 | Peritoneal Dialysis Fluid and Some of Its Components Potentiate Fibrocyte Differentiation. |
| Q64084950 | Peritoneal Dialysis Vintage and Glucose Exposure but Not Peritonitis Episodes Drive Peritoneal Membrane Transformation During the First Years of PD |
| Q26740468 | Peritoneal Dialysis in Western Countries |
| Q36632854 | Peritoneal Fluid Transport rather than Peritoneal Solute Transport Associates with Dialysis Vintage and Age of Peritoneal Dialysis Patients |
| Q38106610 | Peritoneal changes in patients on long-term peritoneal dialysis |
| Q42226666 | Peritoneal dialysis tailored to pediatric needs |
| Q38539729 | Peritoneal dialysis: from bench to bedside |
| Q37492333 | Peritoneal function in clinical practice: the importance of follow-up and its measurement in patients. Recommendations for patient information and measurement of peritoneal function |
| Q46408607 | Peritoneal morphologic changes in a peritoneal dialysis rat model correlate with angiopoietin/Tie-2. |
| Q36475639 | Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan |
| Q34725067 | Peritoneal resting with heparinized lavage reverses peritoneal type I membrane failure. A comparative study of the resting effects on normal membranes |
| Q38187841 | Pharmacologic targets and peritoneal membrane remodeling |
| Q50528626 | Pharmacological inhibition of heparin-binding EGF-like growth factor promotes peritoneal angiogenesis in a peritoneal dialysis rat model. |
| Q37232277 | Phenotypes of encapsulating peritoneal sclerosis--macroscopic appearance, histologic findings, and outcome |
| Q36605072 | Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions |
| Q30433297 | Preventive effect of Notch signaling inhibition by a gamma-secretase inhibitor on peritoneal dialysis fluid-induced peritoneal fibrosis in rats |
| Q35240129 | Previous renal replacement therapy time at start of peritoneal dialysis independently impact on peritoneal membrane ultrafiltration failure |
| Q46102648 | Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates |
| Q38024974 | Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions |
| Q40277283 | Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis |
| Q37970606 | Protective measures against ultrafiltration failure in peritoneal dialysis patients |
| Q42770918 | Proteomics and peritoneal dialysis: early days but clear potential |
| Q36608272 | Quantitative Histomorphometry of the Healthy Peritoneum |
| Q33693392 | Rationale and design of the balANZ trial: A randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function |
| Q27305884 | Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells |
| Q92617913 | Recommendations for pathological diagnosis on biopsy samples from peritoneal dialysis patients |
| Q47128504 | Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children |
| Q54981633 | RhoA/Rho-kinase triggers epithelial-mesenchymal transition in mesothelial cells and contributes to the pathogenesis of dialysis-related peritoneal fibrosis. |
| Q39169019 | Risk factors for drainage-requiring ascites after refractory peritonitis in peritoneal dialysis patients. |
| Q34246008 | Robot-assisted transvaginal peritoneoscopy using confocal endomicroscopy: a feasibility study in a porcine model |
| Q58710420 | Roles of the TGF-β⁻VEGF-C Pathway in Fibrosis-Related Lymphangiogenesis |
| Q41083786 | SAHA Suppresses Peritoneal Fibrosis in Mice |
| Q98564423 | SIRT1-modified human umbilical cord mesenchymal stem cells ameliorate experimental peritoneal fibrosis by inhibiting the TGF-β/Smad3 pathway |
| Q92522559 | ST2 blockade mitigates peritoneal fibrosis induced by TGF-β and high glucose |
| Q35320766 | Serum response factor accelerates the high glucose-induced Epithelial-to-Mesenchymal Transition (EMT) via snail signaling in human peritoneal mesothelial cells |
| Q53120016 | Should sodium removal in peritoneal dialysis be estimated from the ultrafiltration volume? |
| Q48651768 | Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group |
| Q38542830 | Stability of the combination of ceftazidime and cephazolin in icodextrin or pH neutral peritoneal dialysis solution |
| Q47974720 | Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis |
| Q41751976 | Suppression of peritoneal thickening by histamine in a mouse model of peritoneal scraping |
| Q85208809 | Suramin inhibits the development and progression of peritoneal fibrosis |
| Q36531194 | Syndecan-1 (CD138) deficiency increases Staphylococcus aureus infection but has no effect on pathology in a mouse model of peritoneal dialysis |
| Q35237374 | Syndecan-1 in the mouse parietal peritoneum microcirculation in inflammation |
| Q27002418 | T Helper 17/Regulatory T Cell Balance and Experimental Models of Peritoneal Dialysis-Induced Damage |
| Q37202739 | TGF-β1 promotes lymphangiogenesis during peritoneal fibrosis |
| Q92908775 | Tamoxifen and bone morphogenic protein-7 modulate fibrosis and inflammation in the peritoneal fibrosis model developed in uremic rats |
| Q47096709 | Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition |
| Q33655394 | Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis |
| Q34985928 | Thalidomide prevents the progression of peritoneal fibrosis in mice |
| Q41605086 | The Association of Effluent Ca125 with Peritoneal Dialysis Technique Failure |
| Q30243902 | The Current State of Peritoneal Dialysis |
| Q90163600 | The Effect of Rituximab on Encapsulated Peritoneal Sclerosis in an Experimental Rat Model |
| Q40926537 | The Natural Time Course of Membrane Alterations During Peritoneal Dialysis Is Partly Altered by Peritonitis |
| Q86949355 | The PPARβ/δ agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFκB pathway in rats |
| Q64928401 | The Peritoneal Surface Proteome in a Model of Chronic Peritoneal Dialysis Reveals Mechanisms of Membrane Damage and Preservation. |
| Q91792353 | The Role of Cathepsin B in Peritoneal Fibrosis due to Peritoneal Dialysis |
| Q38602815 | The Role of Tyrosine Kinase Receptors in Peritoneal Fibrosis |
| Q36510083 | The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis |
| Q54349833 | The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis. |
| Q47093916 | The anti-inflammatory pathway regulated via nicotinic acetylcholine receptors in rat intestinal mesothelial cells. |
| Q36474231 | The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products |
| Q42407656 | The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial |
| Q35647457 | The first peritonitis episode alters the natural course of peritoneal membrane characteristics in peritoneal dialysis patients |
| Q35864265 | The local inflammatory responses to infection of the peritoneal cavity in humans: their regulation by cytokines, macrophages, and other leukocytes |
| Q45906510 | The peritoneal-renal syndrome. |
| Q26780108 | The potential role of NFAT5 and osmolarity in peritoneal injury |
| Q40110085 | The promising future of long-term peritoneal dialysis |
| Q89691154 | The role of WNT5A and Ror2 in peritoneal membrane injury |
| Q36913752 | The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis |
| Q35524650 | The solution to better preservation of the peritoneal membrane still lies hidden in the solution |
| Q53433459 | The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis. |
| Q36474329 | Time course of peritoneal function in automated and continuous peritoneal dialysis |
| Q35573614 | Treatment of severe ultrafiltration failure with nonglucose dialysis solutions in patients with and without peritoneal sclerosis |
| Q39896017 | Ultrafiltration Failure and Impaired Sodium Sieving During Long-Term Peritoneal Dialysis: More Than Aquaporin Dysfunction? |
| Q44948298 | Ultrasonographic evaluation of peritoneal membrane thickness and comparison with the effectiveness and duration of CAPD. |
| Q36000601 | Vascular Endothelial Cell Injury Is an Important Factor in the Development of Encapsulating Peritoneal Sclerosis in Long-Term Peritoneal Dialysis Patients |
| Q55054604 | Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury. |
| Q92939191 | miR-200c Prevents TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Fibrogenesis in Mesothelial Cells by Targeting ZEB2 and Notch1 |
| Q26779972 | microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis |
Search more.